Search
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigational[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position … of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ASTONIN-H 0,1 MG TABLET, 100 ADET, FLORINEF TABLET 0.1 mgAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalBy replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).
Products: STRENSİQ 40 MG/1.0 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 80 MG/0.8 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETErgotamine
go.drugbank.com/drugs/DB00696ApprovedA vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Mixtures: CAFERGOT 1 MG/100 MG TABLET, 30 ADET, ERGOTAMINA/CAFEINA 1/100 MGCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsEptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. … Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Products: EPTICARD 20 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET, INTEGRILIN IV INFUSION 0.75 mg/mlMivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnIt binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Products: MIVACRON INJECTION 10 mg/5 ml, MİVACRON 10 MG/5 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADETFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalThe manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acidArsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: LEUSENOX 10 MG/10 ML IV INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN AMPUL, 10 ADET, LEUSENOX 10 MG/10 ML IV INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN AMPUL, 1 ADETSemaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses.
Products: WEGOVY® 0.5-1.0 MG/DOSIS (1.34 MG/ML), RYBELSUS 3 MG TABLET, 60 ADETFerric ammonium citrate
go.drugbank.com/drugs/DB09501ApprovedWithdrawnProducts: FOLITON 250 MG/5 ML ŞURUP, 120 ML, KİNAMALT SİROP, 250 GClobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 SubstratesSynonyms: 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate